Did You Know...
...During the Civil War, the Confederacy established its own Patent Office which issued 266 patents, a third of which concerned implements of war.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8153138 | Recombinant MVA virus The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use... | 04/10/2012 |
| 8142796 | Monoparamunity inducers based on attenuated rabbit myxomaviruses The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the ... | 03/27/2012 |
| 8124105 | Compositions, methods and kits relating to poxvirus subunit vaccines The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the prote... | 02/28/2012 |
| 8039004 | Methods of preparing myxomavirus compositions The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the ... | 10/18/2011 |
| 8034356 | Monoparamunity inducers based on attenuated rabbit myxoma viruses The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the ... | 10/11/2011 |
| 7976850 | treatment A vaccine composition for combating Pox viridae viral infections in living organisms such as mammals (including humans) comprises TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity. The composition... | 07/12/2011 |
| 7939086 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes... | 05/10/2011 |
| 7939085 | Monoparamunity inducers based on attenuated rabbit myxomaviruses The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the ... | 05/10/2011 |
| 7923017 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes... | 04/12/2011 |
| 7897156 | Modified vaccinia virus ankara for the vaccination of neonates The invention concerns the use of a virus to increase the number of dendritic cells or their precursor cells in an immunocompromised animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara which is capable of infecting the cells of a neon... | 03/01/2011 |
| 7887814 | Interferon antagonists useful for the treatment of interferon related diseases The present invention relates to a process for ameliorating or preventing diseases that are caused, in part, by an increased level of, and/or an abnormal responsivity to, interferon. Specifically, the invention provides compositions and methods for preventing and tr... | 02/15/2011 |
| 7807180 | Poxvirus methods and compositions Methods and compositions for inducing immune responses against poxviruses are disclosed. The compositions include nucleic acids that encode modified vaccinia and variola antigens. Compositions that include recombinant vaccinia and variola polypeptides are also discl... | 10/05/2010 |
| 7799329 | Viruses for the treatment of cellular proliferative disorders Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Prol... | 09/21/2010 |
| 7790182 | Protein vaccines against poxviruses The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R... | 09/07/2010 |
| 7691391 | Monoparamunity inducers based on attenuated rabbit myxomaviruses The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the ... | 04/06/2010 |
| 7670607 | Pharmaceutical compositions for treating papillomavirus tumors and infection A pharmaceutical composition for treating or preventing a papillomavirus infection or tumor, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide h... | 03/02/2010 |
| 7662398 | Microorganisms for therapy Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, ... | 02/16/2010 |
| 7645456 | Vaccinia virus strains The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines. ... | 01/12/2010 |
| 7638134 | Insertion sites in fowlpox vectors The present invention provides novel insertion sites for introducing DNA into pox vectors. ... | 12/29/2009 |
| 7588771 | Microorganisms for therapy Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, ... | 09/15/2009 |
| 7514087 | Methods and reagents for immunization which generate a CD8 T cell immune response New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composi... | 04/07/2009 |
| 7410644 | Recombinant pox virus for immunization against tumor-associated antigens Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen. ... | 08/12/2008 |
| 7393533 | H3L envelope protein immunization methods and H3L envelope passive protection methods The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositi... | 07/01/2008 |
| 7384644 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or ... | 06/10/2008 |
| 7384643 | Recombinant poxvirus Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group. ... | 06/10/2008 |
| 7374768 | Viral vaccines A mutant virus for use as a vaccine for prophylaxis or therapy, wherein the genome of the virus is defective in respect of a gene essential for the production of infectious virus. In one aspect the mutant virus, e.g. a herpesvirus, e.g HSV-1 or HSV-2, is capable of ... | 05/20/2008 |
| 7368116 | Method of enhancing a targeted immune response against tumors The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encod... | 05/06/2008 |
| 7354591 | Poxvirus with targeted infection specificity The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule loca... | 04/08/2008 |
| 7348014 | Poxvirus with targeted infection specificity The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule loca... | 03/25/2008 |
| 7338662 | Recombinant poxvirus expressing homologous genes inserted into the foxviral genome The sent invention relates to a recombinant poxvirus vector capable of expressing two or more homologous, foreign sequences, which derive from different variants of a microorganism, and which have a homology of 50% or above. The invention further relates to a method... | 03/04/2008 |
| 7335364 | Modified Vaccinia Ankara virus variant The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus... | 02/26/2008 |
| 7300658 | Recombinant poxvirus comprising at least two compox ATI promoters Recombinant poxvirus are disclosed comprising in the viral genome at least two expression cassettes, each comprising a cowpox ATI promoter according to SEQ ID NO:1, a polynucleotide sequence in which not more than 6 nucleotides are substituted, deleted, and/or inser... | 11/27/2007 |
| 7279166 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric in... | 10/09/2007 |
| 7276353 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric in... | 10/02/2007 |
| 7276242 | Vipox vector coding an HIV antigen and a cytokine The invention relates to a fowl pox virus encoding an HIV antigen (gag and/or pol) and a cytokine (γ-interferon). ... | 10/02/2007 |
| 7273605 | Vaccine The present invention relates to a fowlpox virus genome which has modifications in one or more wild-type FPV genes. The present invention also relates to a viral particle comprising such a genome and its use to deliver a nucleotide of interest (NOI) to a target cell... | 09/25/2007 |
| 7255862 | ALVAC/FIV constructs Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment, attenuated recombinant viruses containing DNA encoding a feline immunodefic... | 08/14/2007 |
| 7217526 | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been ide... | 05/15/2007 |
| 7208313 | Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype. ... | 04/24/2007 |
| 7198934 | Recombinant MVA virus, and the use thereof The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use... | 04/03/2007 |
